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Abstract: The use of nucleoside reverse transcriptase inhibitors in the treatment of HIV infection is associated with 
antiretroviral toxic polyneuropathy (ATN). Previous studies suggest that long term treatment with Acetyl-L-carnitine 
(ALCAR) 1.5 gram twice daily improves symptoms and promotes nerve regeneration. It is unknown whether the drug’s 
pharmacokinetic profile would allow for a once daily administration. Twenty three HIV-1 infected subjects taking AL-
CAR for ATN were enrolled in a cross over trial and switched from twice to once daily dosing. Their regimen was 
changed from 1.5g twice daily to 1g (4 patients), 2g (7), and 3g (12) once daily, respectively. Twelve healthy volunteers 
served as control. Plasma levels of ALCAR and its metabolite L-carnitine were measured. Patients receiving ALCAR had 
higher pre-dose levels than control subjects. Post dose levels were not significantly higher than pre dose levels in any 
treatment group. The pre / post dose ALCAR concentrations were 7.6 / 7.7, 7.1 / 6.8, 7.7 / 6.8, and 7.1 / 7.5 mol/l for 
1.5g twice daily, 1g once daily, 2g once daily, and 3g once daily, respectively. All values were significantly higher than 
the mean concentration in the control group (4.3 mol/l). For ALCAR and L-carnitine, measurements for once daily 
regimens did not differ from the twice daily regimen. Once daily dosing of ALCAR can achieve similar plasma levels as 
twice daily dosing but intra-mitochondrial levels remain unknown. The pharmacokinetic profile of orally administered 
ALCAR is complex and likely to be highly affected by endogenous concentrations. 
INTRODUCTION 
  Highly active antiretroviral therapy (HAART) is the cur-
rent standard treatment for HIV infection but is associated 
with long term side effects. Nucleoside reverse transcriptase 
inhibitors (NRTI’s), a major component of HAART, are as-
sociated with distal symmetrical polyneuropathy (DSP) [1]. 
This antiretroviral toxic neuropathy (ATN) occurs mainly 
but not exclusively with dideoxynucleotide analogue agents, 
e.g. stavudine and didanosine, and causes significant morbid-
ity in 10-35% of patients [2,3]. 
  NRTI’s interfere with mitochondrial metabolism by re-
ducing neuronal mitochondrial DNA synthesis leading to a 
disruption of oxidative metabolism [1,4-6]. Subsequently, 
peripheral axons die back as the neuronal mitochondria are 
unable to meet their metabolic requirements. Histological 
examination confirms reduced epidermal innervation in af-
fected areas [7,8]. 
  Acetyl-L-carnitine (ALCAR) is an ester of L-carnitine 
and plays a major role in normal mitochondrial function, 
being a transport molecule for free fatty acids and an impor-
tant acetyl-group donor in high-energy metabolism and free 
fatty acid beta-oxidation [9,10]. Its main body stores are in 
skeletal and cardiac muscle. It is found along with free 
plasma L-carnitine and other acyl-esters of varying chain   
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length [11]. The formation of ALCAR originates with cyto-
plasmic thiokinase which forms acyl-Coenzyme A from free 
fatty acids, ATP and Coenzyme A (CoA) [12]. This sub-
stance is combined with carnitine to form acetyl-carnitine via 
carnitine palmitoyltransferase I. Entry into the mitochondrial 
matrix occurs through an exchange system of acylcarnitine / 
carnitine  via  carnitine-acylcarnitine translocase. For each 
acylcarnitine molecule traversing the inner mitochondrial 
membrane, a molecule of carnitine is shuttles out. On the 
inner mitochondrial membrane, carnitine palmitoyltrans-
ferase II converts acylcarnitine to carnitine, liberating acyl-
CoA. Finally, the production of ALCAR and CoA from car-
nitine and acetylCoA (obtained via beta-oxidation of acyl-
CoA) occurs via  carnitine acetyltransferase present in the 
mitochondrial matrix [12,13]. The enzymatic formation of 
ALCAR in the mitochondrial matrix is reversible, releasing 
free Coenzyme A and acetylCoA which can readily be ex-
changed across membranes, thus providing metabolic energy 
to intracellular organelles. 
  ALCAR plasma levels are decreased in HIV positive 
patients suffering from ATN [14]. It appears that certain 
pathways of carnitine metabolism, such as the acetylation of 
carnitine to acetyl-carnitine, are impaired, possibly as a re-
sult of the toxicity of antiretroviral medication. 
  Oral treatment with ALCAR (1.5g twice daily) has 
shown some beneficial effect on symptoms and nerve regen-
eration in patients with ATN [15-18]. It is unknown whether 
the pharmacokinetic profile would allow a once daily ad-
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METHODS 
  The study was approved by the Royal Free Ethics Com-
mittee, London. Consent was obtained from all patients. The 
inclusion criteria for this cross over trial were: Male or fe-
male patients with confirmed HIV-1 infection (ELISA anti-
body testing), a stable antiretroviral combination that re-
mained unchanged throughout the study, a clinical diagnosis 
of antiretroviral toxic neuropathy, and ALCAR therapy (1.5 
g twice daily) for at least 3 months. Plasma samples for the 
measurement of ALCAR and L-carnitine levels were taken 
pre-dose (fasting) and 2-hour post-dose. Subsequently, the 
twice daily dose was changed to a range of once daily doses 
(1g, 2g, and 3g). Plasma sampling was repeated after 4 
weeks. 
  Healthy volunteers, recruited from laboratory staff served 
as control. None of them was known to be HIV infected nor 
taking ALCAR. 
  Sensitive high pressure liquid chromatography (HPLC) 
with fluorometric detection as described elsewhere [19], was 
used for the measurement of ALCAR and L-carnitine in 
blood plasma. The procedure involves pre-column derivitisa-
tion with 1-aminoanthrecene performed in phosphate buffer 
in the presence of 1-(3-dimethylaminopropyl)-3-ethylcar-
bodiimide hydrochloride as catalyst. The fluorescent deriva-
tives were isocratically separated on a reversed-phase col-
umn. The eluate was monitored with fluorometric detector 
set at 248 nm (excitation wavelength) and 418 nm (emission 
wavelength). At the concentrations measured, the assay has 
been found to have an imprecision of less than 10%, as de-
termined in preceding measurements. All plasma samples 
were processed and analysed in duplicate. A standard curve 
was plotted prior to each analytical run. 
  The data was normally distributed. A Student’s t-test was 
used for analysis with statistical significance set at p<0.05. 
RESULTS 
  Twenty-three HIV infected subjects on ALCAR therapy 
and 12 HIV uninfected control subjects were enrolled and 
completed the study. There were slightly more men in the 
treatment group and the control group was younger (Table 
1). Six patients in the treatment group were taking one 
NRTI, 13 were taking two NRTIs, 3 were taking 3 NRTIs in 
combination with 1-2 protease inhibitors (PI) and / or non-
nucleoside reverse transcriptase inhibitors (NNRTI). One 
patient was taking an antiretroviral regime consisting of a PI 
and an NNRTI only. From 1.5 g ALCAR twice daily (23 
patients, plasma levels from 15 patients obtained), the treat-
ment was changed to once daily doses of 1g (4 patients), 2g 
(7 patients), or 3g (12 patients), respectively. 
  The plasma levels are shown in Table 2 and Figs. (1) and 
(2). When compared with the control group, all ALCAR 
plasma levels (pre and post dose) were significantly higher 
in the treatment groups (p < 0.02). For L-carnitine, all post 
dose level were significantly higher than in the control group 
(p < 0.03). Pre dose levels, however, were only significantly 
higher in the groups taking 1.5g twice daily (p = 0.03) or 2g 
once daily (p = 0.008). Accordingly, post dose levels were 
significantly higher than pre dose levels in patients taking 1g 
or 3g once daily (p < 0.05). There was no significant differ-
ence between any of the plasma levels (ALCAR and L-
carnitine) in the treatment groups. In particular, there was no 
difference between once daily and twice daily regimen. 
DISCUSSION 
  As previously shown, plasma ALCAR levels are de-
creased in patients with ATN [14,20]. Oral ALCAR supple-
mentation seems to result in plasma levels that are higher 
than in healthy individuals. Our findings may therefore pro-
vide indirect support for reports that ALCAR promotes nerve 
fibre regeneration and can improve neuropathic symptoms 
[15-18]. 
  No significant differences in plasma levels were seen in 
the different dosage groups despite a reduction of the total 
daily dose by up to two thirds (from 1.5g twice daily to 1g 
once daily). However, our study size was small and its re-
sults need to be interpreted with caution. The metabolism of 
ALCAR and L-carnitine is complex. It has been shown that 
 
Fig. (1). ALCAR plasma levels (bid: twice daily, od: once daily). Pharmacokinetics of Acetyl-L-Carnitine  The Open AIDS Journal, 2008, Volume 2    41 
peripheral blood monocytes in AIDS patients are low in in-
tracellular L-carnitine [21]. Serum levels, however, may be 
high, low or normal and are therefore unreliable as an indica-
tor of L-carnitine metabolism [22]. 
  L-carnitine and ALCAR homeostasis are maintained by 
absorption from diet, a modest rate of synthesis, very effi-
cient renal re-absorption and probably renal tubular secre-
tion. Dietary ALCAR is hydrolysed partially during absorp-
tion in enterocytes, partially after absorption. Both ALCAR 
and L-carnitine plasma concentrations have been found to 
return to baseline within 12 hours after injection [23]. The 
key mechanism for this seems to be renal re-absorption that 
displays saturation kinetics. With rising L-carnitine concen-
trations, re-absorption decreases and clearance increases. 
This results in a rapid decline of circulating L-carnitine. 
Elimination kinetics for ALCAR are similar to those for L-
carnitine [23]. 
  Our data suggest that oral supplementation of ALCAR 
may increase the steady state concentration of ALCAR in 
blood plasma until its saturated renal kinetics prevent a fur-
ther rise. However, continuous treatment with ALCAR may 
lead to mitochondrial storage which could explain why there 
is no significant difference between pre and post dose levels 
in most treatment groups. It may also explain why plasma 
levels remained elevated for more than 12 hours in contrast 
to reports on intravenous application [23]. 
Table 1.  Baseline Characteristics (SD: Standard Deviation) 
 
 ALCAR  Group 
(n=23) 
Control Group 
(n=12) 
Men %  87 75 
Mean age in years (range)  43 (34 to 60)  35 (27 to 62) 
Time of HIV infection in years 
(SD)  10.5 (5.1)  NA 
Subjects with previous HIV 
related disease  7 0 
Patients with <50 cc/ml viral 
load  12 12 
 
  However, it remains unknown whether high plasma lev-
els are associated with high intra-mitochondrial levels. Given 
that the pathogenesis of antiretroviral toxic neuropathy is 
based on the disruption of mitochondrial energy supply one 
can assume that the clinical effect of ALCAR is dependent 
 
Fig. (2). L-carnitine plasma levels (bid: twice daily, od: once daily). 
Table 2.  Mean Plasma Levels in mol/l (Standard Deviation) 
 
  1.5g ALCAR Twice Daily 
(n=15*) 
1g ALCAR Once Daily 
(n=4) 
2g ALCAR Once Daily 
(n=7) 
3g ALCAR Once Daily 
(n=12) 
Control Group 
(n=12) 
pre-dose  7.6 (2.3)  7.1 (2.9)  7.7 (2.0)  7.1 (3.6) 
A
L
C
A
R
 
2hrs post-dose  7.7 (2.2)  6.8 (1.7)  6.8 (1.3)  7.5 (2.9) 
4.3 (0.9) 
pre-dose  52.8 (18.3)  48.3 (8.1)  51.0 (8.2)  49.0 (15.5) 
L
-
c
a
r
n
i
t
i
n
e
 
2hrs post-dose  52.1 (17.9)  50.6 (7.5)  53.0 (5.0)  54.3 (16.9) 
40.2 (7.0) 
* Values for 15 of 23 patients were obtained. 42    The Open AIDS Journal, 2008, Volume 2  Herzmann et al. 
on its mitochondrial availability. There are, unfortunately, no 
readily available tests to evaluate mitochondrial toxicity of 
NRTIs nor intra-mitochondrial concentrations of ALCAR. 
  It appears that once daily and twice daily doses of AL-
CAR can achieve similar plasma levels. Therefore the easier 
administration schedule may be equally effective for the 
treatment of antiretroviral toxic neuropathy. Trials are 
needed to compare the clinical effect on symptoms and nerve 
regeneration. 
ABBREVIATIONS 
ALCAR = Acetyl-L-Carnitine 
ATN =  Antiretroviral  toxic  neuropathy 
bid =  Twice  daily 
CoA =  Coenzyme  A 
DSP  =  Distal symmetrical polyneuropathy 
ELISA  =  Enzyme linked immunosorbent assay 
NRTI  =  Nucleoside reverse transcriptase inhibitors 
od =  Once  daily 
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